



Antifungal Resistance: Current Trends and Future Strategies

Guest Editors:

Dr. Matthew Donadu

1. Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy

2. Hospital Pharmacy, Azienda Ospedaliero Universitaria di Sassari, 07100 Sassari, Italy

Dr. Basem Battah

Department of Biochemistry and Microbiology, Faculty of Pharmacy, Syrian Private University (SPU), Daraa International Highway, Daraa, Syria

Deadline for manuscript submissions:

closed (31 October 2023)

Message from the Guest Editors

For decades, fungal infections have been a difficult health condition to treat. This can be attributed to the narrow spectrum and high toxicity of clinically used antifungals, the long duration of treatment, and the high emergence of resistance towards available agents. The severity of fungal infections was brought to light during the unfortunate COVID-19 pandemic, in the form of life-threatening secondary infections in intensive care units. *Candida*, *Cryptococcus*, and *Aspergillus* are the most common causative organisms of life-threatening human fungal infections. *Candida auris* is a multidrug resistant fungus. *Lomentospora prolificans* has intrinsic resistance to all clinically used antifungals. *Aspergillus fumigatus* is becoming more resistant to treatment, making it more difficult to treat aspergillosis, with the mortality rate reaching 100% in some cases. Early diagnosis and treatment of fungal meningitis and chronic pulmonary aspergillosis can save millions of lives worldwide. Fungal infections have become a silent crisis, and immediate efforts are needed before it is too late. In this Special Issue, we will highlight current cutting-edge developments in the antifungal pipeline.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Lawrence S. Young

Warwick Medical School,
University of Warwick, Coventry
CV4 7AL, UK

Message from the Editor-in-Chief

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics. *Pathogens* is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*General Immunology and Microbiology*)

Contact Us

Pathogens Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pathogens
pathogens@mdpi.com
[X@Pathogens_MDPI](https://twitter.com/Pathogens_MDPI)